3-hydroxyanthranilic acid has been researched along with Diabetes Mellitus, Type 2 in 2 studies
3-Hydroxyanthranilic Acid: An oxidation product of tryptophan metabolism. It may be a free radical scavenger and a carcinogen.
3-hydroxyanthranilic acid : An aminobenzoic acid that is benzoic acid substituted at C-2 by an amine group and at C-3 by a hydroxy group. It is an intermediate in the metabolism of the amino acid tryptophan.
3-hydroxyanthranilate : A hydroxybenzoate that is the conjugate base of 3-hydroxyanthranilic acid.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In individuals with prediabetes, 3-hydroxykynurenine (OR per SD 0." | 8.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
| "Several kynurenines were cross-sectionally associated with lower odds of cognitive impairment and better cognitive functioning in type 2 diabetes, while less widespread associations were seen in prediabetes." | 8.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
| "In individuals with type 2 diabetes, kynurenine (0." | 5.62 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
| " In individuals with prediabetes, 3-hydroxykynurenine (OR per SD 0." | 4.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
| "Several kynurenines were cross-sectionally associated with lower odds of cognitive impairment and better cognitive functioning in type 2 diabetes, while less widespread associations were seen in prediabetes." | 4.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
| "In individuals with type 2 diabetes, kynurenine (0." | 1.62 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
| "About 350 million people worldwide have type 2 diabetes (T2D)." | 1.42 | Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes. ( Oxenkrug, GF, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakker, L | 1 |
| Ramakers, IHGB | 1 |
| van Boxtel, MPJ | 1 |
| Schram, MT | 1 |
| Stehouwer, CDA | 1 |
| van der Kallen, CJH | 1 |
| Dagnelie, PC | 1 |
| van Greevenbroek, MMJ | 1 |
| Wesselius, A | 1 |
| Midttun, Ø | 1 |
| Ueland, PM | 1 |
| Verhey, FRJ | 1 |
| Eussen, SJPM | 1 |
| Köhler, S | 1 |
| Oxenkrug, GF | 1 |
2 other studies available for 3-hydroxyanthranilic acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study.
Topics: 3-Hydroxyanthranilic Acid; Aged; Biomarkers; Blood Glucose; Cognition; Cognitive Dysfunction; Cross- | 2021 |
Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes.
Topics: 3-Hydroxyanthranilic Acid; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agen | 2015 |